More news in the ongoing Dendreon/Provenge saga. The FDA has agreed to amend Dendreon's Special Protocol Assessment (SPA) for a Phase III trial of Provenge, the company's prostate cancer treatment candidate. The amended SPA accelerates the expected timing of the trial results by about one year. Release